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ABSTRACT
The catechol-O-methyltranferase (COMT) is one of the
main enzymes that metabolise dopamine in the brain.
The Val158Met polymorphism in the COMT gene
(rs4680) causes a trimodal distribution of high (Val/Val),
intermediate (Val/Met) and low (Met/Met) enzyme
activity. We tested whether the Val158Met
polymorphism is a modiﬁer of the age at onset (AAO) in
Parkinson’s disease (PD). The rs4680 was genotyped in
a total of 16 609 subjects from ﬁve independent cohorts
of European and North American origin (5886 patients
with PD and 10 723 healthy controls). The multivariate
analysis for comparing PD and control groups was based
on a stepwise logistic regression, with gender, age and
cohort origin included in the initial model. The
multivariate analysis of the AAO was a mixed linear
model, with COMT genotype and gender considered as
ﬁxed effects and cohort and cohort-gender interaction as
random effects. COMT genotype was coded as a
quantitative variable, assuming a codominant genetic
effect. The distribution of the COMT polymorphism was
not signiﬁcantly different in patients and controls
(p=0.22). The Val allele had a signiﬁcant effect on the
AAO with a younger AAO in patients with the Val/Val
(57.1±13.9, p=0.03) than the Val/Met (57.4±13.9) and
the Met/Met genotypes (58.3±13.5). The difference was
greater in men (1.9 years between Val/Val and Met/Met,
p=0.007) than in women (0.2 years, p=0.81). Thus,
the Val158Met COMT polymorphism is not associated
with PD in the Caucasian population but acts as a
modiﬁer of the AAO in PD with a sexual dimorphism:
the Val allele is associated with a younger AAO in men
with idiopathic PD.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative dis-
order characterised by the loss of dopaminergic
neurons in the mesencephalon. The diagnosis of
PD is usually made when patients ﬁrst notice symp-
toms of motor dysfunction (bradykinesia, tremor
and rigidity) that are related to loss of
the dopaminergic innervation in the striatum.
However, the dopaminergic deﬁciency in the
mesencephalon remains clinically silent until
the concentration of dopamine has decreased by
60–80% in the striatum, and until 30–40% loss of
dopaminergic neurons has been reached (1–7).
Compensatory mechanisms may thus be involved
to explain this delay in the occurrence of motor
symptoms.
In the central nervous system, two main
enzymes, the monoamine oxidase B (MAOB) and
the catechol-O-methyltranferase (COMT) metabol-
ise dopamine. The human COMT gene (OMIM
116790) is localised on chromosome 22q11.2. The
distribution of COMT activity in the population
and in families indicates that it is regulated by a
single autosomal locus with two codominant
alleles.1 2 The substitution of valine (Val) by
methionine (Met) at codon 158 (Val158Met) in the
membrane-bound isoform, corresponding to codon
108 in the soluble form, results in a trimodal distri-
bution of high, low and intermediate enzymatic
activity. COMT activity is threefold to fourfold
higher in the liver and red blood cells of 158Val
patients than in those with the 158Met variant.3 4
There are ethnic differences in the distribution of
the Val158Met genotype.5 About 25% of the
Caucasian population is homozygous for the low
activity variant (Met/Met), 25% is homozygous for
the high activity variant (Val/Val) and 50% has the
intermediate activity variant (Val/Met).6
The inﬂuence of the COMT Val158Met poly-
morphism on non-motor symptoms in PD, particu-
larly cognitive functions, has been studied7–11
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but little is known about its effect on motor symptoms. In the
present study, we hypothesise that COMT activity might modu-
late the age at onset (AAO) of motor symptoms in PD by modi-
fying the bioavailability of the remaining endogenous dopamine
in the striatum. Using the COMT Val158/108Met polymorph-
ism as a surrogate marker of enzyme activity, we performed an
association study in 16 609 patients and controls of European
and North American origin.
PATIENTS AND METHODS
French samples
Subjects with PD (n=1031) were recruited through the French
network for the study of Parkinson’s disease genetics associating
15 university hospitals across France. All patients were of
European origin. Deﬁnite and probable PD was deﬁned accord-
ing to the UK Parkinson’s Disease Society Brain Bank
(UKPDSBB).12 The healthy controls (n=2061) of the French
sample came from either the French Three-City (3C) cohort
(n=1933)13 or the Parkinson’s disease genetics network
(n=128). The participants of the 3C cohort were non-
institutionalised subjects over 65 years of age, randomly selected
from the electoral rolls of three French cities. The control sub-
jects were matched for gender with patients with PD.
German samples
The German samples consisted of three independent cohorts
(Kiel, Lübeck and Tübingen). Patients with PD (n=648) and
healthy controls (n=688) from the Kiel sample were from the
Population Based Assessment of Genetic Risk Factors for PD
study performed in northern Germany in cooperation with the
Populationsgenetik (POPGEN) biobank.14 All participating
patients with PD were diagnosed by board certiﬁed neurologists
according to the UKPDSBB Criteria.12 Controls (n=688), also
obtained by POPGEN, were matched to the cases by gender and
geographical origin and were screened to conﬁrm the absence
of PD. The Lübeck sample consisted of 525 cases and 223
healthy controls collected in specialised outpatient clinics. All
patients underwent a detailed neurological examination by a
movement disorder specialist and the diagnosis of PD was estab-
lished clinically according to the UKPDSBB.12 The controls
underwent the same neurological examination as the patients.
The PD cases (n=662) for the Tübingen cohort were collected
by movement disorders specialists at the Universities of Munich
and Tübingen, according to the UKPDSBB.12 Sample collection
from controls (n=767) was performed as part of the
Prospective validation of risk markers for the development of
idiopathic Parkinson’s disease (Idiopathic Parkinson Kohorte
Syndroms, PRIPS) study in Tübingen.
International Parkinson’s Disease Genomics Consortium
Genome-wide association studies-based data from three contribut-
ing cohorts from the International Parkinson’s Disease Genomics
Consortium was used in this study and have been described in
detail elsewhere.15 16 This includes 937 cases of PD and 3033 con-
trols from the US samples from the National Institute on Aging
cohort, 744 cases and 2019 controls from the Dutch cohort, and
1648 cases and 2699 controls from the UK cohort.17–19
All these studies were carried out in accordance with the
Declaration of Helsinki and the rules for clinical good practice.
All participants gave their informed consent. The local Ethical
Committees approved the studies.
AAO deﬁnition
AAO was systematically determined at the time of inclusion
by a retrospective interview. The AAO was deﬁned as the ﬁrst
PD-related motor symptom (akinesia, tremor or rigidity) experi-
enced by the patient for the French, Lübeck and Tübingen
cohorts, and by the age at which PD was ﬁrst diagnosed for the
Kiel sample and the International Parkinson’s Disease Genomics
Consortium cohorts.
Genotyping
The COMT polymorphism G185A (rs4680) was analysed by an
allelic discrimination Taqman assay (Applied Biosystems PRISM
7900 sequence detection system, Applied Biosystems, Foster
City, USA) for the German samples or extracted from DNA
array studies as described elsewhere.15 16 20–24
Statistical analysis
Descriptive statistics used numbers and percentages as qualita-
tive variables and means and SDs as quantitative variables.
Relationships between qualitative variables were tested using
χ2 tests and comparisons between means of quantitative vari-
ables were performed using Student t tests for two groups and
unbalanced analysis of variance (ANOVA) for more than two
groups. The multivariate analysis for comparing PD and control
groups was based on a stepwise logistic regression, with all vari-
ables included in the initial model and variables statistically sig-
niﬁcant with p<0.05 by the Wald test retained in the ﬁnal
model. The multivariate analysis of the AAO was ﬁrst based on
a mixed linear model, with the COMT genotype and gender
considered as ﬁxed effects and cohort and cohort-gender inter-
action considered as random effects. In a second step, two dis-
tinct models were ﬁtted, one for men and one for women, with
the COMT genotype as the ﬁxed effect and the cohort as the
random effect. In all mixed linear models, the COMT genotype
was coded as a quantitative variable, namely as the number of
‘L’ alleles. Hardy-Weinberg equilibrium was tested using χ2 tests
in each sample. All tests were two-sided, with a p value of 0.05
considered statistically signiﬁcant. Computations were per-
formed using the SAS V.9 statistical package.
RESULTS
Characteristics of patients and controls
A total of 17 665 subjects were available (6177 patients with PD
and 11 488 controls). Due to insufﬁcient DNA quantity or
quality or missing clinical information 1056 specimens were
excluded for further analysis. Finally, 16 609 subjects were
genotyped for the rs4680 polymorphism and included in the
analysis (5886 patients with PD and 10 723 healthy controls).
Table 1 Characteristics of subjects
PD Controls
n Sex ratio AAO n Sex ratio Age at inclusion
All 5886 1.5 57.6±13.8 10723 1.01 60.0±10.1
US 937 1.5 57.8±13.2 3033 0.89 63.3±10.1
UK 1648 1.4 64.2±12.4 2699 1.07 53.0±0.0
NL 744 1.8 55.6±11.8 2019 0.79 55.7±5.8
France 1031 1.3 48.4±13.2 2061 1.20 73.0±6.4
Germany 1526 1.5 57.4±13.0 911 1.14 50.2±15.7
AAO, age at onset; n, number of subjects; NL, Netherlands; Sex ratio, male/female;
PD, Parkinson’s disease; US, North-American.
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The characteristics of subjects in the ﬁve cohorts are summarised
in table 1. The mean AAO for patients with PD was
57.6±13.8 years. Cohorts of patients with PD were signiﬁcantly
different in terms of AAO (p<0.001) and sex ratio (p=0.04).
The mean AAO was also signiﬁcantly different between gender
(male 57.1±13.7, female 58.3±13.9, p=0.001). Subsequent
analyses thus included gender and cohorts in the multivariate
model.
Distribution of the COMT polymorphism
The distribution of the Val158Met polymorphism in the dataset
is described in table 2. The distribution of the single nucleotide
polymorphism (SNP) was in Hardy-Weinberg equilibrium in
patients (p=0.44) and controls groups (p=0.25). The distribu-
tion of genotypes (Val/Val, Val/Met and Met/Met) was similar
and not signiﬁcantly different in patients and controls (table 2,
p=0.22). However, genotype distributions differed signiﬁcantly
among cohorts (p<0.001). The multivariate analysis including
gender, cohorts and the age of PD and controls in the model
found no signiﬁcant association between the Val158Met poly-
morphism and PD (p=0.22). Altogether, these results failed to
ﬁnd an association between rs4680 and PD in a large popula-
tion of Caucasian patients with PD and controls.
AAO and COMT polymorphism
The AAO was analysed assuming a genetic codominant model
for the Val158Met COMT polymorphism in accordance with its
codominant effect on the enzyme activity. A signiﬁcant differ-
ence of AAO was found for the French (47.9±13.3 for Val/Val
compared with 50.2±13.1 for Met/Met, p=0.04) and the US
samples (56.2±13.4 for Val/Val compared with 59.5±12.7 for
Met/Met, p=0.03). For the UK, Dutch and German samples no
signiﬁcant changes could be found (data not shown).
The univariate analysis for the whole PD sample (n=5886)
found a signiﬁcant difference of AAO according to genotype
with an earlier AAO for those carrying the Val158 allele, corre-
sponding to the high enzyme activity (table 3, p=0.04). The
multivariate analysis conﬁrmed the signiﬁcant association of the
AAO with the COMT polymorphism when cohorts and gender
were included in the model (p=0.03). The difference of AAO
was 1.2 years earlier for patients with the Val/Val genotype com-
pared with patients with the Met/Met genotype (57.1±13.9 vs
58.3±13.5, p=0.017). Interestingly, this difference was
higher in male patients (56.0±14.1 for Val/Val compared with
57.9±13.6 for Met/Met, p=0.007) than in female patients
(58.6±13.4 for Val/Val compared with 58.8±13.3 for Met/Met,
p=0.81) (table 3).
DISCUSSION
This is the largest study in which the COMT polymorphism
rs4680 (Val158Met) was genotyped in PD in 16 609 patients
and controls from different European and North American
samples. We show that the rs4680 polymorphism is a genetic
modiﬁer of the AAO in patients with idiopathic PD. Our results
suggest a codominant effect of the COMT Val158Met poly-
morphism resulting in a modiﬁcation of the AAO by 1.2 years
between extreme genotypes (Val/Val and Met/Met). This effect
was signiﬁcant in men but not in women with a 1.9 years differ-
ence between extreme genotypes in men. This modifying effect
was not associated with an increased risk of PD associated with
the Val158Met polymorphism. This result conﬁrms, in a larger
cohort, the absence of association between this polymorphism
and PD risk in the Caucasian population.7 25–27 In the French
and US samples we revealed a signiﬁcant earlier AAO associated
with the Val/Val genotypes. In the remaining samples from
Germany, the Netherlands and the UK no signiﬁcant result has
been shown. A possible explanation might be that these samples
were underpowered.
The effect of the COMT Val158Met polymorphism on AAO
might be explained by a difference of metabolism of the
endogenous dopamine in the striatum at disease onset. Indeed,
patients carrying the Val158 allele (Val/Val and Val/Met) may
have a reduced dopamine bioavailability because of a higher
enzyme activity leading to earlier motor symptoms. Conversely,
poor metabolisers (Met/Met) may have a greater dopamine bio-
availability delaying their motor symptoms. The inverse U curve
effect of dopamine concentration in the frontal cortex28 was
elegantly validated in studies of working memory in healthy
controls and schizophrenic patients demonstrating that the
Val158Met COMT polymorphism has indeed functional conse-
quences on brain function.29 30 In PD, studies on the impact of
the Val158Met polymorphism on non-motor symptoms have
produced conﬂicting results.7–11 No evidence was found for an
association between the Val158Met genotype and daytime
sleepiness or on neuropsychological measures of attention and
executive function.9 10 Other studies showed that the genotype
directly affects executive function in early stage PD; Val/Val
patients have less frontoparietal activation on fMRI11 and better
performance on executive tasks.8 11 A pharmacogenetic study
showed that the COMT polymorphism determines the acute
response to entacapone,31 although the motor response to levo-
dopa alone was not modiﬁed by the COMT polymorphism.31 32
These results collectively show that the COMT polymorphism
modiﬁes the PD phenotype. Considering its frequency, it might
have to be taken into account in the clinical management of
patients with PD.
An interesting result in our study was the gender difference of
the COMT genotype effect on AAO. The AAO was not signiﬁ-
cantly different in women whereas it was 1.9 years earlier in men
Table 2 Distribution of the COMT Val158Met polymorphism in PD
and controls
Total (% (n)) Control (% (n)) PD (% (n)) p Value
Val/Val 23.7 (3943) 23.6 (2526) 24.1 (1417) 0.22
Val/Met 49.5 (8214) 49.5 (5303) 49.5 (2911)
Met/Met 26.8 (4452) 27.0 (2894) 26.5 (1558)
Val/Val: homozygous for the Val158 allele; Val/Met: heterozygous; Met/Met:
homozygous for the Met158 allele. p Value: multivariate analysis (see material and
methods).
COMT, catechol-O-methyltranferase; PD, Parkinson’s disease.
Table 3 Age at onset in patients with PD according to COMT
Val158Met genotype
Met/Met Val/Met Val/Val
Univariate
p value
Multivariate
p value
Total 58.3±13.5 57.4±13.9 57.1±13.9 0.041 0.026*
Men 57.9±13.6 57.1±13.6 56.0±14.1 0.013 0.007**
Women 58.8±13.3 57.7±14.3 58.6±13.4 0.29 0.81**
*Multivariate model including cohorts and gender as cofactors.
**Multivariate model including cohorts as cofactor.
Val/Val: homozygous for the Val158 allele; Val/Met: heterozygous; Met/Met:
homozygous for the Met158 allele.
COMT, catechol-O-methyltranferase; PD, Parkinson’s disease.
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with the Val/Val genotype compared with the Met/Met genotype.
A sexually dimorphic autosomal genetic association of the
COMT gene has been well-recognised in psychiatric disorders
but has not yet been described in PD. One of the best-replicated
ﬁndings was the association of low enzymatic activity with
obsessive-compulsive disorder in men, but not in women.33–35 In
postmortem studies, the dorsolateral prefrontal cortex of women
had lower COMT activity than men.36 Further evidence
for gender differences comes from COMT knockout mice
(COMT-/-).37 In this model dopamine levels in the frontal cortex
are signiﬁcantly increased in male COMT-/- mice compared with
wild-type mice, but not in female COMT -/- mice. Sex hormones,
especially oestrogen, probably contribute to explain gender dif-
ferences. Oestrogens inhibit COMT mRNA expression in cells
expressing oestrogen receptors.38 However the oestrogen
hypothesis might only be a part of the explanation of the gender
dimorphism in our study because (1) oestrogen levels fall in post-
menopausal women, the age at which PD commonly occurs and
(2) in mid-age men the COMT protein and activity levels rise
considerably,39 despite steady oestradiol levels within this
period.40 Bearing this in mind further pathophysiological mech-
anism could be responsible for the sexual dimorphism like add-
itional gene implication or epigenetic regulation.41 A candidate
gene involved in gender differences could be the monoamine
oxidase B (MAOB; OMIM 309860), an X linked gene, which also
participates in dopamine metabolism. The MAOB brain activity
increases with age42 and its activity is regulated by epigenetic
factors.43 Different SNPs of the MAOB44 and the combination of
genotypes at risk for the MAOB and the COMT gene45 were sus-
pected to be associated with PD. Interestingly, one MAOB SNP
(rs1799836) was available in French patients with PD (n=992).
In this subset, no signiﬁcant association was found between AAO
and this MAOB SNP either alone or in combination with the
COMTrs4680 (data not shown).
Our study may have some limitations although statistical biases
were carefully avoided by performing multivariate analyses
adjusting for cohort origin and gender. Because non-motor—and
non-dopaminergic symptoms—may precede motor symptoms in
PD, disease onset might not adequately reﬂect dopaminergic
denervation in the striatum that might be modiﬁed by the
COMT. Finally, other environmental modiﬁers, like tobacco, are
also likely to contribute to the development of PD symptoms but
environmental factors were not available in our dataset. Genetic
forms of PD as well as genetic susceptibility factors such as muta-
tions in the galactocerebrosidase gene were not systematically
screened. Indeed, an association between heterozygous galacto-
cerebrosidase gene mutation and the AAO has been suspected in
PD.46 Future studies must integrate the effects of environmental
and genetic factors, including the COMT polymorphism, that
could affect the bioavailability of dopamine in general, and espe-
cially in individuals at risk for PD.
In conclusion, our data indicate that the COMT polymorph-
ism rs4680 (Val158Met) is a genetic modiﬁer of AAO in patients
with PD, with a higher effect in male patients than in female
patients. This may be important for future diagnostic and thera-
peutic strategies.
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